Targeted therapy (TKIs) for kidney cancer — the tablet that goes after the tumour’s blood supply

Targeted therapy is a group of tablet medicines that block a specific pathway the cancer depends on, rather than attacking all rapidly dividing cells the way chemotherapy does. In kidney cancer the usual target is the tumour's blood supply. Kidney cancers push out signals that make new blood vessels grow towards them, and a targeted drug interrupts those signals inside the cell that receives them. The class most often used is a VEGF tyrosine kinase inhibitor, usually shortened to VEGF TKI. It is used for kidney cancer that has spread or come back, not for early disease that surgery has cleared. At CION targeted therapy is prescribed and monitored in-house by our medical oncology team, along NCCN lines.

Clear cell kidney cancer, the commonest type, usually begins with a fault in the VHL gene. That fault stops a protein called HIF being cleared as it normally would. HIF builds up, and the cell behaves as though it were short of oxygen - so it releases growth signals, chief among them VEGF, which tells nearby blood vessels to sprout new branches towards the tumour. A VEGF TKI works on the receiving end of that signal. It blocks the switch inside the vessel cell that would otherwise pass the message on. New vessel growth slows and the tumour's supply line is squeezed. That is why targeted therapy for kidney cancer is described as anti-angiogenic - it works against the growth of new blood vessels.

They are not rivals, and for most people the question is not which one but which combination. Current guidance for advanced clear cell kidney cancer usually opens with an immune-based approach - either two immunotherapy drugs together, or a PD-1 inhibitor paired with a VEGF TKI - so targeted therapy is frequently part of first treatment rather than an alternative to it. A targeted tablet on its own is still the right choice in some situations, for example where immunotherapy is not suitable because of an existing autoimmune condition or an organ transplant. Which route is put forward depends on the tumour type, your IMDC risk group, your other medical conditions and your own priorities. At CION that decision goes to a tumour board, not to one doctor.

It is a tablet or capsule taken at home, not a drip, so there is no admission and no day-care chair. Some are taken every day without a break; others follow a set rhythm of some weeks on and some weeks off. You will be given a written schedule and asked to keep to it, and to check with the team before starting any new medicine, supplement or herbal remedy, because several interact. Treatment continues for as long as it is working and you are tolerating it - it is not a fixed course of a set number of cycles. Reviews are frequent at the start, with blood pressure, thyroid, liver and kidney checks, and scans at intervals to see how the disease is responding.

Because the drug blocks a pathway the healthy body also uses, the effects tend to be predictable and dose-related rather than random. The ones seen most often are raised blood pressure, tiredness, diarrhoea, soreness of the palms and soles, mouth soreness, a change in taste, and an underactive thyroid. Most are handled by treating the effect itself or by adjusting the dose, and a dose reduction is a normal part of finding the right balance - it is not a sign that treatment has failed. Blood pressure is checked at every visit and often at home as well. Tell your team early rather than waiting for the next appointment, because small problems handled early are what keep people on treatment comfortably.

No. It was developed around clear cell kidney cancer, where the VHL pathway makes the blood-supply target especially relevant. Papillary, chromophobe and the rarer types behave differently, treatment for them is decided case by case, and entry to a clinical trial is considered where a suitable one is open. Targeted therapy is also not given for early kidney cancer that surgery has removed completely - there the discussion is about surveillance, and about adjuvant immunotherapy in selected higher-risk cases. If you have a non-clear-cell type, it is fair to ask specifically what the recommendation is based on, because the evidence for those types is thinner and the decision is more individual.